Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients

Demırsoy, Esra Terzı; Mehtap, Özgür; Atesoglu, Elif Birtas; Tarkun, Pınar; Gedük, Ayfer; Eren, Necmi; Hacıhanefioğlu, Abdullah

doi:10.1007/s12288-021-01470-5

Cited by 2 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is certain, however, that the relationship between plasma cell disorders and FGF-23 is complex and insufficiently understood. Improved understanding of those mechanisms could potentially significantly decrease morbidity associated with bone disease of multiple myeloma, especially considering that Terzi Demirsoy et al [ 49 ] found that patients with elevated FGF-23 levels had decreased overall survival, indicating that FGF-23 either does have a role in the pathogenesis of myeloma or that it could simply be a marker of more advanced disease.…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Hypophosphatemia in Patients With Multiple Myeloma

Cancarevic¹,

Ilyas²,

Nassar³

2023

Cureus

View full text Add to dashboard Cite

Hypophosphatemia is among the most common electrolyte abnormalities, especially among patients with underlying malignancies, and is frequently associated with adverse prognoses. Phosphorus levels are regulated through a number of mechanisms, including parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), vitamin D, and other electrolyte levels themselves. Clinically, the findings are nonspecific, and the diagnosis is frequently delayed. This article is a narrative literature review. The PubMed database was searched for relevant articles pertaining to hypophosphatemia causes and consequences in patients suffering from multiple myeloma. We found a variety of causes of hypophosphatemia in patients with multiple myeloma. Tumor-induced osteopenia, although more common among patients with small squamous cell carcinomas, can occur with multiple myeloma as well. Additionally, both light chains themselves and medications can trigger Fanconi syndrome, which leads to phosphorus wasting by the kidney. Bisphosphonates, in addition to being a possible cause of Fanconi syndrome, lead to a decrease in calcium levels, which then stimulates parathyroid hormone (PTH) release, predisposing the patient to significant hypophosphatemia. Additionally, many of the more modern medications used to manage multiple myeloma have been associated with hypophosphatemia. A better understanding of those mechanisms may give clinicians a clearer idea of which patients may need more frequent screening as well as what the potential triggers in the individual patient may be.

show abstract

Section: Reviewmentioning

confidence: 99%

“…Fanconi syndrome, a condition involving proximal tubules of the nephron, is characterized by renal wasting of several substrates, including phosphorus [ 49 ]. It can be triggered by various medications, including antibiotics, chemotherapies, and primary conditions, such as hematologic malignancies (Figure 2 ) [ 19 , 50 ].…”

Section: Reviewmentioning

confidence: 99%

Hypophosphatemia in Patients With Multiple Myeloma

Cancarevic¹,

Ilyas²,

Nassar³

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…It has been established that KLOTHO and FGF23 genes regulate calcium and phosphorus metabolism [25]. The prognostic value of serum KLOTHO and FGF23 proteins was revealed in patients with multiple myeloma [26]. Research was made of the role of KLOTHO and FGF23 genes in cardiovascular disorders in diabetic patients with chronic threatening limb ischemia [27].…”

Section: Introductionmentioning

confidence: 99%

piRNAs and miRNAs Can Bind to mRNA of <i>KLOTHO</i> and <i>FGF23</i> Genes

Ivashchenko,

Akhmetova,

Zhanuzakov

et al. 2023

Preprint

View full text Add to dashboard Cite

The problem of increasing life expectancy is solved with the help of many medical and social areas. It has been established that piRNAs and miRNAs can significantly modify the expression of protein-coding genes by suppressing the translation process. The aim of this work was to establish the possibility of binding piRNAs and miRNAs with mRNA of the KLOTHO and FGF23 genes, which promote health and increase life expectancy through participation in key metabolic processes. We used the MirTarget program, which determines the quantitative characteristics of complementary interactions of all piRNAs and miRNAs nucleotides with mRNA of the genes. piR-44682, piR-1940042, piR-3008660, piR-3215034, piR-6885965, piR-7980636 and one miRNA (ID00756.3p-miR) binding to the mRNA of the KLOTHO gene were found in one cluster of binding sites (BSs). piRNA-6890096 interacted with the mRNA of KLOTHO gene in a fully complementary manner using only canonical nucleotides. Among 17494 human genes, target genes interacting with five piRNAs that bind to the mRNA of KLOTHO gene were identified. mRNA of the AFF2, BCL2L11, CPT1A, DAZAP1, NDRG3, SKIDA1, WBP4, ZIC5, ZSWIM6 genes interacted with piR-3215034 and piR-6885965, which formed clusters of BSs located in 5'UTR, CDS and 3'UTR. The piR-576442, piR-1501557, piR-1845735, piR-2069834, and piR-3029987 had BSs in the mRNAs of the FGF23 gene, located only in the 3'UTR. It is proposed to use piRNAs and miRNAs as regulators of the expression of KLOTHO and FGF23 anti-aging genes.

show abstract

Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients

Cited by 2 publications

References 33 publications

Hypophosphatemia in Patients With Multiple Myeloma

Hypophosphatemia in Patients With Multiple Myeloma

piRNAs and miRNAs Can Bind to mRNA of <i>KLOTHO</i> and <i>FGF23</i> Genes

Contact Info

Product

Resources

About